Stockscreener 앱 받기
40.91
0.20%
-0.08
시간 외 거래:
41.30
0.39
+0.95%
전일 마감가:
$40.99
열려 있는:
$40.87
하루 거래량:
4.50M
Relative Volume:
1.46
시가총액:
$7.75B
수익:
$2.83B
순이익/손실:
$-1.02B
주가수익비율:
-7.4247
EPS:
-5.51
순현금흐름:
$194.14M
1주 성능:
-12.64%
1개월 성능:
-21.19%
6개월 성능:
-19.88%
1년 성능:
-28.24%
1일 변동 폭
$40.55
$41.57
1주일 범위
$38.81
$48.02
52주 변동 폭
$38.81
$72.83
이그젝트 사이 Stock (EXAS) Company Profile
명칭
Exact Sciences Corp
전화
608-284-5700
주소
5505 ENDEAVOR LANE, MADISON, WI
EXAS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
EXAS
Exact Sciences Corp
|
40.91 | 7.76B | 2.83B | -1.02B | 194.14M | -5.51 |
|
TMO
Thermo Fisher Scientific Inc
|
462.39 | 173.97B | 43.21B | 6.58B | 6.17B | 17.29 |
|
DHR
Danaher Corp
|
199.76 | 143.61B | 24.01B | 3.41B | 4.86B | 4.70 |
|
IDXX
Idexx Laboratories Inc
|
652.11 | 52.65B | 4.04B | 985.66M | 774.34M | 12.01 |
|
A
Agilent Technologies Inc
|
114.13 | 32.56B | 6.63B | 1.17B | 1.19B | 4.05 |
|
IQV
Iqvia Holdings Inc
|
180.09 | 30.58B | 15.50B | 1.33B | 2.16B | 7.34 |
이그젝트 사이 Stock (EXAS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-10 | 개시 | Mizuho | Outperform |
| 2025-03-13 | 개시 | RBC Capital Mkts | Sector Perform |
| 2025-01-23 | 개시 | Barclays | Overweight |
| 2024-08-28 | 개시 | Wells Fargo | Overweight |
| 2024-06-27 | 개시 | Scotiabank | Sector Outperform |
| 2024-06-03 | 재개 | Jefferies | Buy |
| 2024-01-02 | 업그레이드 | The Benchmark Company | Hold → Buy |
| 2023-12-14 | 개시 | Guggenheim | Buy |
| 2023-12-13 | 개시 | Wolfe Research | Outperform |
| 2023-10-10 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2023-09-28 | 개시 | Bernstein | Outperform |
| 2023-08-02 | 다운그레이드 | The Benchmark Company | Buy → Hold |
| 2023-05-10 | 업그레이드 | Craig Hallum | Hold → Buy |
| 2023-05-05 | 개시 | UBS | Neutral |
| 2023-03-09 | 업그레이드 | Citigroup | Neutral → Buy |
| 2023-02-10 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2023-01-18 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2022-10-19 | 다운그레이드 | Craig Hallum | Buy → Hold |
| 2022-08-25 | 개시 | Credit Suisse | Outperform |
| 2022-06-03 | 개시 | Piper Sandler | Neutral |
| 2021-11-03 | 다운그레이드 | Raymond James | Strong Buy → Outperform |
| 2021-07-29 | 재확인 | BTIG Research | Buy |
| 2021-07-29 | 재확인 | Canaccord Genuity | Buy |
| 2021-07-29 | 재확인 | Oppenheimer | Outperform |
| 2021-07-29 | 재확인 | Stifel | Buy |
| 2021-06-15 | 개시 | Raymond James | Strong Buy |
| 2021-06-03 | 개시 | Goldman | Buy |
| 2021-05-25 | 개시 | Wells Fargo | Equal Weight |
| 2021-01-28 | 개시 | Truist | Buy |
| 2020-10-29 | 다운그레이드 | UBS | Buy → Neutral |
| 2020-10-28 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2020-10-08 | 재개 | BTIG Research | Buy |
| 2020-04-02 | 개시 | Evercore ISI | Outperform |
| 2020-01-10 | 재개 | BTIG Research | Buy |
| 2020-01-07 | 개시 | Citigroup | Buy |
| 2019-12-13 | 개시 | Dougherty & Company | Buy |
| 2019-11-15 | 개시 | Stifel | Buy |
| 2019-10-17 | 재확인 | BofA/Merrill | Buy |
| 2019-10-01 | 재개 | Craig Hallum | Buy |
| 2019-09-26 | 개시 | Oppenheimer | Outperform |
| 2019-02-26 | 업그레이드 | Goldman | Neutral → Buy |
| 2018-10-09 | 개시 | UBS | Buy |
| 2018-09-05 | 재개 | The Benchmark Company | Hold |
| 2018-08-13 | 재확인 | Canaccord Genuity | Buy |
| 2018-04-03 | 업그레이드 | BTIG Research | Neutral → Buy |
| 2018-01-29 | 개시 | Goldman | Neutral |
| 2018-01-08 | 재확인 | The Benchmark Company | Buy |
| 2017-11-13 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2017-11-01 | 다운그레이드 | BTIG Research | Buy → Neutral |
모두보기
이그젝트 사이 주식(EXAS)의 최신 뉴스
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought - The Motley Fool
Multi Cancer Early Detection Market Forecast Report 2025-2033: A $4.3 Billion Market by 2033, as Market Set to Quadruple from $1 Billion Valuation in 2024 - uk.finance.yahoo.com
Top 3 Health Care Stocks That Are Preparing To Pump This Month - Benzinga
FY2025 EPS Forecast for Exact Sciences Increased by Analyst - Defense World
Applying Elliott Wave Theory to Exact Sciences CorporationEarnings Impact and Stock Reaction Analysis - Newser
How to read the order book for Exact Sciences CorporationFree Real Time Alerts Based on AI Prediction - Newser
Real time social sentiment graph for Exact Sciences CorporationAI Entry Timing Prediction for Swing Traders - Newser
Real time scanner hits for Exact Sciences Corporation explainedTrading Volume Anomaly Summary and Insight - Newser
Avantax Advisory Services Inc. Acquires 1,259 Shares of Exact Sciences Corporation (NASDAQ:EXAS) - Defense World
Leerink Partnrs Forecasts Weaker Earnings for Exact Sciences - Defense World
A Quick Look at Today's Ratings for Exact Sciences(EXAS.US), With a Forecast Between $60 to $70 - 富途牛牛
Exact Sciences Corporation (NASDAQ:EXAS) Q2 2025 Earnings Call Transcript - Insider Monkey
Cathie Wood’s ARK bolsters Exact Sciences, sheds DraftKings stock By Investing.com - Investing.com Australia
Cathie Wood’s ARK bolsters Exact Sciences, sheds DraftKings stock - Investing.com
Exact Sciences (NASDAQ:EXAS) Hits New 1-Year Low Following Analyst Downgrade - Defense World
Exact Sciences Corp’s Strong Earnings Call Highlights - TipRanks
Exact Sciences Dip A Chance To Buy As Freenome Deal Fortifies Future: Analyst - AOL.com
Is Exact Sciences, Down 8%, 'Throwing Good Money At Bad' In Its New Licensing Deal? - Investor's Business Daily
Why Is Exact Sciences Stock Tumbling Thursday?Exact Sciences (NASDAQ:EXAS) - Benzinga
Exact Sciences Earnings: Blood-Based Test Misses Cutoff for Medicare Reimbursement - Morningstar
Exact Sciences Leads the Colorectal Cancer Screening Market, but Uncertainty Lies Ahead - Morningstar
Exact Sciences stock price target lowered to $46 at RBC on growth concerns - Investing.com Canada
Bernstein SocGen lowers Exact Sciences stock price target to $60 - Investing.com
Exact Sciences (EXAS) Secures Rights to Freenome's Cancer Screening Tests - GuruFocus
UBS Adjusts Exact Sciences Price Target to $53 From $61, Maintains Neutral Rating - MarketScreener
Exact Sciences stock price target lowered to $66 by TD Cowen after blood test setback - Investing.com
Piper Sandler reiterates Overweight rating on Exact Sciences stock By Investing.com - Investing.com Canada
Piper Sandler reiterates Overweight rating on Exact Sciences stock - Investing.com
Exact Sciences Reports Strong Q2 2025 Revenue GrowthNews and Statistics - IndexBox
Exact Sciences Corp. Exceeds Q2 Earnings ExpectationsNews and Statistics - IndexBox
Exact Sciences price target lowered to $55 from $65 at Barclays - TipRanks
Exact Sciences Q2 2025 Earnings Call Transcript - MarketBeat
Exact Sciences to acquire US rights for Freenome’s blood-based CRC test - Yahoo Finance
Exact Sciences: Q2 Earnings Snapshot - Manistee News Advocate
Earnings call transcript: Exact Sciences Q2 2025 beats EPS forecasts - Investing.com
Exact Sciences Q2 2025 slides: Revenue jumps 16%, guidance raised on strong performance - Investing.com Canada
Exact Sciences Corp. Reports Strong Q2 2025 Results - TipRanks
Exact Sciences lays off 4% of company including Madison positions - WMTV 15 NEWS
Freenome Announces Exclusive License Agreement with Exact Sciences to Commercialize Freenome's Blood-Based Screening Test for Colorectal Cancer | Newswise - Newswise
Exact Sciences (EXAS) Q2 Revenue Up 16% - The Globe and Mail
Exact Sciences (NASDAQ:EXAS) Reports Strong Q2 But Stock Drops 15.2% - Yahoo Finance
Exact Sciences Corp reports results for the quarter ended June 30Earnings Summary - TradingView
Exact Sciences shares plunge despite earnings beat By Investing.com - Investing.com Nigeria
Key External Factors That Drive Exact Sciences Corporation Stock Price MovementsReal Stock Picks With Setup Verification - Newser
Exact Sciences shares plunge despite earnings beat - Investing.com
EXACT Sciences earnings beat by $0.12, revenue topped estimates - Investing.com
Exact Sciences Announces Collaboration with Freenome Holdings - TipRanks
Exact Sciences acquires rights to Freenome’s blood-based CRC tests By Investing.com - Investing.com South Africa
Exact Sciences acquires rights to Freenome’s blood-based CRC tests - Investing.com
Earnings Flash (EXAS) Exact Sciences Corp. Posts Q2 Adjusted EPS $0.22 per Share - MarketScreener
Exact Sciences acquires exclusive license for Freenome blood-based CRC tests - StreetInsider
이그젝트 사이 (EXAS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.68%
0.79%
자본화:
|
볼륨(24시간):